U.s. fda lists applied dna's linea™ covid-19 assay kit as 1 of only 2 eua-authorized tests able to detect s-gene mutation found in sars-cov-2 u.k. variant (b.1.1.7)

Stony brook, n.y.--(business wire)---- $apdn #covid19--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in polymerase chain reaction (pcr)-based dna manufacturing, announced today that the u.s. food and drug administration (fda) published a safety communication (the “communication”) that identifies the company's linea™ covid-19 assay kit (the “assay kit”) as one of only two tests marketed under the fda's emergency use authorization (eua) that are potentially able to identify certain sars-cov-2
APDN Ratings Summary
APDN Quant Ranking